Why Drug Developers Choose IgG4 for Monoclonal Antibodies? – Illiasul Ibad
Illiasul Ibad, Rheumatologist at Christian Medical College, posted on X:
”1․ Why are many therapeutic monoclonal antibodies built on the IgG4 framework?
2․ Understand basics
Biology of IgG4
• Least abundant IgG subclass
• Very weak complement activation
• Poor interaction with Fc receptors → almost no ADCC
Translation: IgG4 can block targets without collateral tissue damage.
3․ Fab-arm exchange
Natural IgG4 can swap half its arms → becomes “functionally monovalent.”
Good for tolerance in nature, but bad for drug stability.
Solution: scientists engineered the S228P mutation → no swapping, molecule stays stable.
4․ Why drug developers love IgG4
• Precise blocking, not killing
• Low inflammation risk
• Engineered stability
• Safe for long-term therapy
That’s why IgG4 is the backbone of modern antibody medicines – quiet, stable, effective.”
Stay updated with Hemostasis Today.
-
Nov 29, 2025, 18:55Ahmad Thuaimer: Success Story – Advanced Interventional Care for DVT
-
Nov 29, 2025, 17:37Almahdi Ali Explores Ipsilateral Paradoxical Thromboembolism at 22nd European Angiology Days 2025
-
Nov 29, 2025, 17:23Jack Shuang Hou Shares Major Neurology Updates This Week
-
Nov 29, 2025, 16:52Federica Fogacci on Further Strengthening Collaboration Within the Lp(a)CCELERATE Study
-
Nov 29, 2025, 16:42Dr Abdul Mannan on the Echinocyte: Mastering the Diagnostic Duality of Artifact vs. Pathology
-
Nov 29, 2025, 16:42Vikas Dua: Heme Next 1.0 A Conference with a Difference
-
Nov 29, 2025, 16:41Hind Ali: Sources Of Error in Cell Counts
-
Nov 29, 2025, 16:40Maxime Dely: Even on a Break, You Can Give
-
Nov 29, 2025, 16:39Shrinidhi Nathany: HemeNext Brings Science, Technology, and Leadership Together